Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

First Evidence in Humans That BPA Can Alter Insulin Sensitivity : ScienceAlert (opens in a new tab)

sciencealert.com · 2026-09-15

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 2 supported
  • 4 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Two of six claims match the study. This overall rating is based only on the claims we could check. Four claims the study doesn't address.

  • 2 supported
  • 4 not covered
Open claim evidence
3
Source paper

Source layer

The 5 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6Not coveredThe first experimental evidence in humans has now found that ingesting BPA, even at low doses, may reduce insulin sensitivity in the short term.View evidenceHide evidence

Why this verdict

The abstract-level profile supports the randomized human experimental finding and states that these results were presented as the first experimental human evidence that BPA administration may reduce insulin sensitivity. However, the specific characterization as 'low doses' is not established in the supplied abstract profile beyond the administered dose of 50 µg/kg/day, so that part is not verifiable at this evidence depth.

1

Study evidence

Five days of oral BPA (50 µg/kg/day) decreased peripheral insulin sensitivity compared with placebo in healthy normal-weight adults.−0.02 ± 0.01 mg/kg/min/uU/mL (BPA) vs +0.02 ± 0.01 mg/kg/min/uU/mL (placebo); P = .01

“Bisphenol A decreases peripheral insulin sensitivity in normal weight adults: a double-blind randomized controlled trial”
Claim 2 of 6Not coveredIn a randomized, double-blind clinical trial, 40 young adults were exposed to a 'safe' dose of BPA or a placebo.View evidenceHide evidence

As stated40 young adults

Why this verdict

The profile supports that this was a randomized, double-blind placebo-controlled trial in 40 healthy young adults receiving oral BPA or placebo for 5 days. But the story's description of the administered dose as 'safe' is not supported by the supplied abstract-level profile, which reports the dose as 50 µg/kg/day but does not verify the safety-threshold framing.

1

Study evidence

Five days of oral BPA (50 µg/kg/day) decreased peripheral insulin sensitivity compared with placebo in healthy normal-weight adults.−0.02 ± 0.01 mg/kg/min/uU/mL (BPA) vs +0.02 ± 0.01 mg/kg/min/uU/mL (placebo); P = .01

“Bisphenol A decreases peripheral insulin sensitivity in normal weight adults: a double-blind randomized controlled trial”
Claim 3 of 6Not coveredAfter five days, peripheral insulin sensitivity decreased by 9 percent in the BPA group, while it rose slightly in the placebo group.View evidenceHide evidence

As stated9 percent

Why this verdict

The direction of the effect is supported: peripheral insulin sensitivity decreased in the BPA group and increased in the placebo group, with a between-group P value of .01. But the abstract-level profile reports the effect as −0.02 ± 0.01 mg/kg/min/uU/mL versus +0.02 ± 0.01 mg/kg/min/uU/mL, not as a 9 percent decrease, so the stated percentage magnitude is not verifiable at this depth.

1

Study evidence

Five days of oral BPA (50 µg/kg/day) decreased peripheral insulin sensitivity compared with placebo in healthy normal-weight adults.−0.02 ± 0.01 mg/kg/min/uU/mL (BPA) vs +0.02 ± 0.01 mg/kg/min/uU/mL (placebo); P = .01

“Bisphenol A decreases peripheral insulin sensitivity in normal weight adults: a double-blind randomized controlled trial”
Claim 4 of 6Not coveredThe authors conclude that short-term oral BPA administration may impair insulin sensitivity and that the findings have important clinical and public health implications.View evidenceHide evidence

Why this verdict

The profile supports the authors' conclusion that 5 days of oral BPA administration decreased peripheral insulin sensitivity and may reduce insulin sensitivity in humans. However, the broader statement that the authors concluded the findings have important clinical and public health implications is not present in the supplied abstract-level profile.

1

Study evidence

Five days of oral BPA (50 µg/kg/day) decreased peripheral insulin sensitivity compared with placebo in healthy normal-weight adults.−0.02 ± 0.01 mg/kg/min/uU/mL (BPA) vs +0.02 ± 0.01 mg/kg/min/uU/mL (placebo); P = .01

“Bisphenol A decreases peripheral insulin sensitivity in normal weight adults: a double-blind randomized controlled trial”
Claim 5 of 6SupportedBPA, a ubiquitous industrial chemical used in food and beverage packaging, may quietly mess with the body's insulin sensitivity when ingested.View evidenceHide evidence

Why this verdict

The paper profile supports the main framed claim that oral BPA exposure may reduce peripheral insulin sensitivity: it describes a double-blind randomized placebo-controlled human trial in which 5 days of BPA administration significantly decreased clamp-derived peripheral insulin sensitivity versus placebo. The packaging/ubiquity background is not detailed in the supplied profile, but the insulin-sensitivity claim is supported.

1

Study evidence

Five days of oral BPA (50 µg/kg/day) decreased peripheral insulin sensitivity compared with placebo in healthy normal-weight adults.−0.02 ± 0.01 mg/kg/min/uU/mL (BPA) vs +0.02 ± 0.01 mg/kg/min/uU/mL (placebo); P = .01

“Bisphenol A decreases peripheral insulin sensitivity in normal weight adults: a double-blind randomized controlled trial”
Claim 6 of 6SupportedThe researchers say larger trials are needed, note the participants were young college-aged adults, and caution the findings may not extend to the population as a whole.View evidenceHide evidence

Why this verdict

The profile supports the core caveats: the trial had 40 participants, the mean age was about 21 years, and generalizability is limited by the young, normal-weight, majority non-Hispanic White sample. The supplied profile does not quote 'Larger trials are needed,' but the caveat is consistent with the small-sample limitation.

1

Study evidence

Five days of oral BPA (50 µg/kg/day) decreased peripheral insulin sensitivity compared with placebo in healthy normal-weight adults.−0.02 ± 0.01 mg/kg/min/uU/mL (BPA) vs +0.02 ± 0.01 mg/kg/min/uU/mL (placebo); P = .01

“Bisphenol A decreases peripheral insulin sensitivity in normal weight adults: a double-blind randomized controlled trial”
2

Study evidence

Urine BPA levels were significantly higher in the BPA-50 arm compared with placebo after treatment.+268,700 ± 63,983 vs +8,893 ± 6,786 pg/mL (change from baseline); P = .009

“After treatment, urine BPA levels were significantly higher in BPA-50 compared to PL”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The BPA intervention dose was 50 µg/kg/day.

    The story frames the dose as 'safe' or low/within a safety threshold, but the supplied paper profile's material dose detail is the numerical intervention dose of 50 µg/kg/day; that exact dose is not reflected in the presented claims.

    From Double-blind randomized placebo-controlled trial (parallel); Double-blind randomized controlled trial (parallel groups)

  • Peripheral insulin sensitivity was assessed using a euglycemic hyperinsulinemic clamp.

    The story reports the insulin-sensitivity outcome but does not mention the clamp method, which is a material measurement detail in the paper profile.

    From Double-blind randomized placebo-controlled trial (parallel)

  • Urine BPA increased substantially in the BPA arm, confirming differential exposure.

    The story does not mention the urine BPA biomarker result, which is material because it confirms that the intervention produced substantially higher BPA exposure.

    From Double-blind randomized controlled trial (parallel groups)

  • Body weight and fasting glucose did not differ statistically between groups after treatment.

    The story focuses on insulin sensitivity and does not report the secondary finding that body weight and fasting glucose were not different after treatment.

    From Double-blind randomized controlled trial (parallel groups)

6 things the story did carry across
  • The study was a double-blind randomized placebo-controlled human trial of 5 days of oral BPA versus placebo.
  • The trial enrolled 40 healthy, normal-weight, sedentary young adults.
  • Five days of BPA decreased clamp-derived peripheral insulin sensitivity compared with placebo.
  • The paper presents the finding as the first experimental human evidence that BPA administration may reduce insulin sensitivity.
  • The intervention duration was short, so the findings reflect acute effects only.
  • Generalizability is limited by the small, young, normal-weight, majority non-Hispanic White sample.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

2

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoTest whether 5 days of oral bisphenol A (BPA) administration reduces peripheral insulin sensitivity in healthy normal-weight adults.Double-blind randomized placebo-controlled trial (parallel)Expand

In plain English

Double-blind randomized placebo-controlled trial in 40 healthy, normal-weight, sedentary adults testing 5 days of oral BPA (50 µg/kg/day) versus placebo; peripheral insulin sensitivity was measured pre- and post-intervention using a 120-minute euglycemic hyperinsulinemic clamp (40 mU/m²/min; target glucose 90 mg/dL). Urinary BPA increased with BPA dosing, and BPA administration was associated with a decrease in clamp-derived peripheral insulin sensitivity compared with an increase in the placebo group (group difference P = 0.01). Body weight and fasting glucose did not differ between groups after treatment.

Key findings

  • Five days of oral BPA (50 µg/kg/day) decreased peripheral insulin sensitivity compared with placebo in healthy normal-weight adults.−0.02 ± 0.01 mg/kg/min/uU/mL (BPA) vs +0.02 ± 0.01 mg/kg/min/uU/mL (placebo); P = .01
“Bisphenol A decreases peripheral insulin sensitivity in normal weight adults: a double-blind randomized controlled trial”
2human in vivoDemonstrate exposure fidelity and basic metabolic safety/neutrality over the intervention period (e.g., urine BPA increase; body weight and fasting glucose changes).Double-blind randomized controlled trial (parallel groups)Expand

In plain English

In a double-blind randomized parallel-group trial of 40 healthy young adults, 5 days of oral BPA at 50 µg/kg body weight produced a large increase in urine BPA compared with placebo, while body weight and fasting glucose did not differ between groups after treatment.

Key findings

  • Urine BPA levels were significantly higher in the BPA-50 arm compared with placebo after treatment.+268,700 ± 63,983 vs +8,893 ± 6,786 pg/mL (change from baseline); P = .009
  • Body weight and fasting glucose were not statistically different between placebo and BPA-50 after treatment.No statistically significant difference (P > .05)
“After treatment, urine BPA levels were significantly higher in BPA-50 compared to PL”
What this piece can’t prove
  • Intervention duration was short (5 days), so findings reflect acute effects only.
  • Sample size was 40 and study population was majority non-Hispanic White (85%), limiting generalizability across ages, BMI ranges, and diverse populations.
  • Abstract does not provide full assay methods, exact post-treatment values, or confidence intervals for body weight and fasting glucose.
Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

Crossref, PubMed, Europe PMC · 19 candidate papers

Candidate

Review for "Efficacy and safety of 28‐day treatment with oral insulin ( ORMD ‐0801) in patients with type 2 diabetes: A randomized, placebo‐controlled trial"

2021 · Crossref

Source (opens in a new tab)

And 13 more candidates considered.